[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619248":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":40,"locations":46,"responsibleParty":68,"collaborators":44,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":44,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Capital Development Authority (CDA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Itraconazole Group","EXPERIMENTAL","Participants in this arm will receive oral itraconazole 200 mg once daily for 4 weeks. Treatment will be administered at the Dermatology Department, CDA Hospital, Islamabad. Clinical outcomes will be assessed at the end of therapy using standardized severity scores (erythema, scaling, and pruritus).",[13],"Drug: Itraconazole (200 mg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Fluconazole Group","ACTIVE_COMPARATOR","Participants in this arm will receive oral fluconazole 150 mg on alternate days for 4 weeks. Treatment will be administered at the Dermatology Department, CDA Hospital, Islamabad. Clinical outcomes will be assessed at the end of therapy using standardized severity scores (erythema, scaling, and pruritus).",[19],"Drug: Fluconazole 150 mg",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Itraconazole (200 mg)","Oral itraconazole 200 mg once daily for 4 weeks. Assigned to participants in the Itraconazole Group. FDA-approved antifungal drug being evaluated for comparative effectiveness in resistant tinea corporis.",[9],[27,28],"Sporanox","Arm 1",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Fluconazole 150 mg","Oral fluconazole 150 mg every other day for 4 weeks. Assigned to participants in the Fluconazole Group. FDA-approved antifungal drug being evaluated for comparative effectiveness in resistant tinea corporis.",[15],[34],"Diflucan",[36],{"name":37,"affiliation":38,"role":39},"Urooj Fatima, MBBS","Capital Development Authority (CDA) Hospital Islamabad","PRINCIPAL_INVESTIGATOR",[41],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","+923363005069",null,"urooj29scorpio@gmail.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"CDA Hospital Islamabad","RECRUITING","Islamabad","Punjab Province","46000","Pakistan","PK",{"type":56,"coordinates":57},"Point",[58,59],74.4039,31.6047,{"lat":59,"lon":58},[62,66],{"name":63,"role":42,"phone":64,"phoneExt":44,"email":65},"CDA Hospital, Islamabad","+92 519221334","contactus@cda.gov.pk",{"name":67,"role":39,"phone":44,"phoneExt":44,"email":44},"Urooj Fatima",{"type":69,"investigatorFullName":67,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"SPONSOR_INVESTIGATOR","Principle Investigator (Postgraduate Resident, Dermatology)","100619248","phase-4-comparing-the-efficacy-of-oral-fluconazole-versus-oral-itraconazole-in-treating-resistant-tinea-corporis-100619248",false,"NCT07342153","Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis","FIVIT","Inclusion Criteria:\n\nAdults aged 18-70 years\n\nMale or female\n\nClinical diagnosis of resistant tinea corporis, defined as persistent disease ≥6 months despite topical antifungal therapy\n\nMicroscopic confirmation of fungal hyphae on KOH preparation of skin scrapings\n\nExclusion Criteria:\n\nPrior use of oral antifungal therapy within the past 3 months\n\nRecent antibiotic treatment for superadded bacterial skin infection in the past 1 month\n\nKnown immunosuppressive conditions (e.g., diabetes mellitus, malignancy)\n\nCurrent or recent use of immunosuppressive drugs\n\nPregnant or lactating women","ALL","18 Years","70 Years",{"count":82,"type":83},126,"ESTIMATED","INTERVENTIONAL",[86],"PHASE4","Tinea corporis (commonly called \"ringworm of the body\") is a skin infection caused by fungi that often becomes difficult to treat when it persists despite creams or other medicines. In recent years, many patients have developed infections that do not respond to routine antifungal treatments, which causes long-term itching, redness, and scaling of the skin.\n\nThis study will test two commonly used oral antifungal drugs - fluconazole and itraconazole - in people with resistant tinea corporis. Adults aged 18-70 years who have had persistent disease for at least six months will be enrolled at the Dermatology Department of CDA Hospital, Islamabad.\n\nParticipants will be randomly assigned to one of two groups. One group will receive itraconazole 200 mg once daily for four weeks, and the other group will receive fluconazole 150 mg every other day for four weeks. Neither group will know which medicine they are receiving (blinded allocation).\n\nThe main goal is to find out which medicine works better in achieving complete clinical resolution - meaning no redness, no scaling, no itching, and no visible skin lesions - after four weeks of treatment. Doctors will measure the severity of symptoms using a standard scoring system, and patients will also report their level of itching.\n\nThe findings will help guide doctors in Pakistan and similar regions in choosing the most effective oral antifungal for patients with resistant tinea corporis, improving both treatment success and patient quality of life.",[89,90],"Tinea Corporis","Dermatophytosis",[89,90,92,93,94,95,53],"Antifungal Resistance","Fluconazole","Itraconazole","Randomized Controlled Trial","2026-01-14",{"date":98,"type":99},"2026-01-15","ACTUAL",{"date":101,"type":99},"2025-11-01",{"date":103,"type":83},"2026-03-10",{"name":67,"class":6},1]